Reference SummaryTschida BR, Cancer Res 2017 Dec 1;77(23):6576-6588
Title |
Sleeping Beauty Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors. |
Authors |
Tschida BR; Temiz NA; Kuka TP; Lee LA; Riordan JD; Tierrablanca CA; Hullsiek R; Wagner S; Hudson WA; Linden MA; Amin K; Beckmann PJ; Heuer RA; Sarver AL; Yang JD; Roberts LR; Nadeau JH; Dupuy AJ; Keng VW; Largaespada DA |
Journal |
Cancer Res |
Volume |
77 |
Issue |
23 |
Year |
2017 |
Pages |
6576-6588 |
Abstract |
Hepatic steatosis is a strong risk factor for the development of hepatocellular carcinoma (HCC), yet little is known about the molecular pathology associated with this factor. In this study, we performed a forward genetic screen using Sleeping Beauty (SB) transposon insertional mutagenesis in mice treated to induce hepatic steatosis and compared the results to human HCC data. In humans, we determined that steatosis increased the proportion of female HCC patients, a pattern also reflected in mice. Our genetic screen identified 203 candidate steatosis-associated HCC genes, many of which are altered in human HCC and are members of established HCC-driving signaling pathways. The protein kinase A/cyclic AMP signaling pathway was altered frequently in mouse and human steatosis-associated HCC. We found that activated PKA expression drove steatosis-specific liver tumorigenesis in a mouse model. Another candidate HCC driver, the N-acetyltransferase NAT10, which we found to be overexpressed in human steatosis-associated HCC and associated with decreased survival in human HCC, also drove liver tumorigenesis in a steatotic mouse model. This study identifies genes and pathways promoting HCC that may represent novel targets for prevention and treatment in the context of hepatic steatosis, an area of rapidly growing clinical significance. Cancer Res; 77(23); 6576-88. (c)2017 AACR. |
Links |
J:252310 – MGI References 28993411 – National Library of Medicine/PubMed |
Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
---|---|---|---|---|---|
[not specified]-Gt(ROSA)26Sortm2(sb11)Njen Speer6-ps1Tg(Alb-cre)21Mgn/? TgTn(sb-T2/Onc)68Dla | Liver - Bile duct cholangiocarcinoma |
|
Liver - Bile duct |
0 |
|
[not specified]-Gt(ROSA)26Sortm2(sb11)Njen Speer6-ps1Tg(Alb-cre)21Mgn/? TgTn(sb-T2/Onc)68Dla | Liver hepatocellular adenoma |
|
Liver |
observed |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver hepatocellular adenoma |
|
Liver |
7 - 14 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver hepatocellular adenoma |
|
Liver |
30 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver hepatocellular adenoma |
|
Liver |
12.5 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver hepatocellular adenoma |
|
Liver |
22 |
|
[not specified]-Gt(ROSA)26Sortm2(sb11)Njen Speer6-ps1Tg(Alb-cre)21Mgn/? TgTn(sb-T2/Onc)68Dla | Liver hepatocellular carcinoma |
|
Liver |
observed |
|
C57BL/6J | Liver hepatocellular carcinoma |
|
Liver |
observed |
|
[not specified]-Gt(ROSA)26Sortm2(sb11)Njen Speer6-ps1Tg(Alb-cre)21Mgn/? TgTn(sb-T2/Onc)68Dla | Liver tumor |
|
Liver |
65 - 81 |
|
[not specified]-Gt(ROSA)26Sortm2(sb11)Njen Speer6-ps1Tg(Alb-cre)21Mgn/? TgTn(sb-T2/Onc)68Dla | Liver tumor |
|
Liver |
40 - 78 |
|
[not specified]-Gt(ROSA)26Sortm2(sb11)Njen TgTn(sb-T2/Onc)68Dla | Liver tumor |
|
Liver |
22 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver tumor |
|
Liver |
50 - 91 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver tumor |
|
Liver |
68 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver tumor |
|
Liver |
92 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver tumor |
|
Liver |
50 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver tumor |
|
Liver |
71 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver tumor |
|
Liver |
17 - 43 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver tumor |
|
Liver |
31 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver tumor |
|
Liver |
52 - 78 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver tumor |
|
Liver |
20 |
|
[not specified]-Fahtm1Mgo Gt(ROSA)26Sortm2(sb11)Njen | Liver tumor |
|
Liver |
0 |